Uroplasty, Inc.  

(Public, NASDAQ:UPI)   Watch this stock  
Find more results for UPI
Mar 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.05 - 4.05
Open     -
Vol / Avg. 0.00/124,964.00
Mkt cap 27.68M
P/E     -
Div/yield     -
EPS -0.30
Shares 22.15M
Beta -1.26
Inst. own 51%

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -31.58% -21.78%
Operating margin -31.26% -21.56%
EBITD margin - -20.12%
Return on average assets -60.82% -28.67%
Return on average equity -87.33% -35.81%
Employees 113 -
CDP Score - -


5420 Feltl Road
United States - Map
+1-952-4266140 (Phone)
+1-952-4266171 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company's products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.